BioSpace News Archive

Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), announced today top-line results of the human abuse potential (HAP) study with REL-1017, a novel NMDA receptor (NMDAR) channel blocker and the company’s lead candidate in Phase 3 development for the treatment major depressive disorder (MDD).

Repligen Corporation, a life sciences company focused on bioprocessing technology leadership, reported financial results for its second quarter of 2021.

Leading sleep expert and former president of American Academy of Sleep Medicine to take on a greater role in day-to-day operations of the company

Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that it will present clinical and pre-clinical data, including updated analyses from the Phase 2 STRIVE study and an in vitro evaluation of rezafungin activity against Candida and Aspergillus spp.

Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) (“Infinity” or the “Company”), a clinical-stage biotechnology company developing eganelisib (IPI-549), a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced its second quarter 2021 financial results and provided a corporate update.

NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, announces that it will release its second quarter 2021 financial and operating results for the period ended June 30, 2021 on Tuesday, August 10, 2021 prior to the start of trading.

New patient adds for the U.S. TYMLOS business continue to grow. New TYMLOS patients in Q2, 2021 were up over 40% vs. the same period in 2020.

VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that it will report its financial results for the second quarter ended June 30, 2021, on August 12, 2021, before the market opens.

Ultragenyx Pharmaceutical Inc. announced that the U.S. Food and Drug Administration and the European Commission have granted Orphan Drug Designation for UX053 for the treatment of Glycogen Storage Disease Type III, a metabolic disease that affects more than 10,000 patients in the developed world.

Global Blood Therapeutics, Inc. announced that it will report second quarter 2021 financial results on Tuesday, August 3, 2021, after U.S. financial markets close.